{
    "clinical_study": {
        "@rank": "40101", 
        "arm_group": [
            {
                "arm_group_label": "Standard treatment", 
                "arm_group_type": "No Intervention", 
                "description": "patients randomized to standard treatment will not receive hydroxychloroquine."
            }, 
            {
                "arm_group_label": "Hydroxychloroquine", 
                "arm_group_type": "Experimental", 
                "description": "Patients will be randomized to receive standard of care or standard of care + hydroxychloroquine. Dose will be weight-adjusted: 200 mg daily for patients weighing <60kg; and 400 mg daily (200 mg twice a day)for patients weighing >60kg."
            }
        ], 
        "brief_summary": {
            "textblock": "In this multi-center international study, our aim is to determine the effectiveness of HCQ\n      for primary thrombosis prophylaxis in persistently aPL-positive but thrombosis-free patients\n      without systemic autoimmune diseases."
        }, 
        "brief_title": "Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients", 
        "completion_date": {
            "#text": "February 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Antiphospholipid Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Thrombosis", 
                "Antiphospholipid Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Randomized to receive HCQ or no treatment in addition to their standard regimen.  11 study\n      visits and 10 phone visits over 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Persistent(at least 12 weeks apart)aPL-positivity within 12 months prior to the\n             screening defined as:\n\n               -  aCL IgG/M (>40U,medium-to-high titer,and/or greater than the 99th\n                  percentile)and/or\n\n               -  a\u03b22GPI IgG/M(>40U, medium-to-high titer, and/or greater than the 99th\n                  percentile)and/or\n\n               -  Positive LA test based on the International Society of Thrombosis & Haematosis\n                  Recommendations\n\n        Selected Exclusion Criteria:\n\n          -  History of thrombosis (arterial, venous, and/or biopsy proven  microthrombosis\n\n          -  History of Transient Ischemic Attack Confirmed by a Neurologist\n\n          -  SLE Diagnosis based on the ACR Classification Criteria > 4/11\n\n          -  Other Systemic Autoimmune Diseases diagnosed based on ACR Classification    Criteria\n\n          -  Current Hydroxychloroquine or another antimalarial treatment (-3 months)\n\n          -  Current warfarin treatment (-3 months)\n\n          -  Current heparin therapy( -3 months)\n\n          -  Current pregnancy\n\n          -  History of Hydroxychloroquine eye toxicity\n\n          -  History of Hydroxychloroquine allergy\n\n          -  Known glucose-6-phosphate dehydrogenase deficiency"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01784523", 
            "org_study_id": "11179"
        }, 
        "intervention": {
            "arm_group_label": "Hydroxychloroquine", 
            "intervention_name": "Hydroxychloroquine", 
            "intervention_type": "Drug", 
            "other_name": "plaquenil"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Hydroxychloroquine", 
                "Antibodies, Antiphospholipid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "antiphospholipid autoantibodies", 
            "antiphospholipid positive"
        ], 
        "lastchanged_date": "April 7, 2014", 
        "link": {
            "description": "APS ACTION", 
            "url": "http://www.apsaction.org"
        }, 
        "location": {
            "contact": {
                "email": "vegaj@hss.edu", 
                "last_name": "JoAnn Vega", 
                "phone": "212-774-2795"
            }, 
            "contact_backup": {
                "email": "ramong@hss.edu", 
                "last_name": "Glendalee Ramon", 
                "phone": "212 774-2808"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Hospital for Special Surgery"
            }, 
            "investigator": {
                "last_name": "Doruk Erkan, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective Randomized Controlled Trial of Hydroxychloroquine in the Primary Thrombosis Prophylaxis of aPL Positive But Thrombosis-free Patients.", 
        "overall_contact": {
            "email": "vegaj@hss.edu", 
            "last_name": "JoAnn Vega", 
            "phone": "212 774-2795"
        }, 
        "overall_contact_backup": {
            "email": "ramong@hss.edu", 
            "last_name": "Glendalee Ramon", 
            "phone": "212 774-2808"
        }, 
        "overall_official": {
            "affiliation": "Hospital for Special Surgery, New York", 
            "last_name": "Doruk Erkan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the efficacy of Hydroxychloroquine in the primary thrombosis prevention of persistently aPL-positive but thrombosis free patients with no other systemic autoimmune diseases over the five year study period.", 
            "measure": "Incident acute thrombosis", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "reference": [
            {
                "PMID": "22635205", 
                "citation": "Erkan D, Lockshin MD; APS ACTION members. APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. Lupus. 2012 Jun;21(7):695-8. doi: 10.1177/0961203312437810."
            }, 
            {
                "PMID": "21303838", 
                "citation": "Erkan D, Derksen R, Levy R, Machin S, Ortel T, Pierangeli S, Roubey R, Lockshin M. Antiphospholipid Syndrome Clinical Research Task Force report. Lupus. 2011 Feb;20(2):219-24. doi: 10.1177/0961203310395053."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01784523"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital for Special Surgery, New York", 
            "investigator_full_name": "Doruk Erkan", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "In persistently aPL-positive patients with no other systemic autoimmune diseases, to determine:\nThe thrombosis incidence rate\nThe effect of Hydroxychloroquine on mortality rate\nThe effect of Hydroxychloroquine on aPL profile", 
            "measure": "thrombosis incidence rate", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "source": "Hospital for Special Surgery, New York", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "APS ACTION", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "NY Community Trust Fund", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Hospital for Special Surgery, New York", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}